Related Experiment Video
Updated: Mar 7, 2026
08:19
Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
Published on: June 1, 2012
15.1K
Glucose-Responsive Insulin Delivery by Microneedle-Array Patches Loaded with Hypoxia-Sensitive Vesicles
Jicheng Yu1,2,3, Yuqi Zhang1,2,3, Zhen Gu4,5,6,7
1Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Methods in Molecular Biology (Clifton, N.J.)
|February 27, 2017
Summary
This study details glucose-responsive vesicles (GRVs) made from hypoxia-sensitive hyaluronic acid (HS-HA) for insulin delivery. These GRVs were loaded into microneedle patches, showing potential for diabetes treatment via transcutaneous administration.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Nanotechnology
Background:
- Diabetes mellitus, particularly type 1, requires precise insulin management.
- Current insulin delivery methods face challenges in achieving physiological responsiveness.
- Development of smart drug delivery systems is crucial for improved therapeutic outcomes.
Purpose of the Study:
- To synthesize hypoxia-sensitive hyaluronic acid (HS-HA) for glucose-responsive vesicle (GRV) formation.
- To fabricate microneedle-array patches loaded with GRVs for transcutaneous insulin delivery.
- To evaluate the in vivo efficacy of the GRV-loaded microneedle patches in a type 1 diabetes mouse model.
Main Methods:
- Synthesis of hypoxia-sensitive hyaluronic acid (HS-HA).
- Formation of glucose-responsive vesicles (GRVs) using HS-HA.
- Fabrication of microneedle-array patches incorporating GRVs.
- In vivo efficacy assessment in a chemically induced type 1 diabetes mouse model.
Main Results:
- Successful preparation of glucose-responsive vesicles (GRVs) using HS-HA.
- Fabrication of functional microneedle-array patches capable of carrying GRVs.
- Demonstration of in vivo efficacy of the smart patch in a type 1 diabetes mouse model.
Conclusions:
- The developed GRVs and microneedle patches offer a promising approach for smart insulin delivery.
- Hypoxia-sensitive hyaluronic acid is a viable component for glucose-responsive systems.
- Transcutaneous administration via microneedles shows potential for effective diabetes management.
Related Concept Videos
01:05Insulin Secretory Vesicles
7.2K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.2K
01:27Insulin Formulations: Types and Delivery
901
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
901
01:15Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.9K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.9K
01:06Oral Hypoglycemic Agents: Glinides
780
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
780
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K